News & Updates
Filter by Specialty:
Lebrikizumab helps clear skin of teens with moderate-to-severe atopic dermatitis
Treatment with lebrikizumab with or without topical corticosteroids (TCS) results in clinical improvement among adolescents with moderate-to-severe atopic dermatitis (AD), according to a study presented at the recent AAD 2023.
Lebrikizumab helps clear skin of teens with moderate-to-severe atopic dermatitis
12 Apr 2023
Ripretinib improves survival in advanced gastrointestinal stromal tumours
Treatment with ripretinib provides a prolonged clinical and radiological benefit in patients with advanced gastrointestinal stromal tumours (GIST) within the expanded access program (EAP) in the UK, as shown in a study presented at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.
Ripretinib improves survival in advanced gastrointestinal stromal tumours
11 Apr 2023
Upadacitinib delivers sustained PRO improvements in AD
Data presented at AAD 2023 underpin the potential of upadacitinib, a selective Janus kinase inhibitor, to provide long-term improvements in patient-reported outcomes (PROs; skin symptoms, sleep, and quality of life [QoL]) in individuals with moderate-to-severe atopic dermatitis (AD).